Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
2 Biotech Stocks That Could Make You Richer
04:15pm, Wednesday, 02'nd Feb 2022 The Motley Fool
These two companies are down, but they aren't yet out.
2 Biotech Stocks That Could Make You Richer
11:15am, Wednesday, 02'nd Feb 2022
These two companies are down, but they aren't yet out.
Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y
05:25pm, Wednesday, 26'th Jan 2022 Zacks Investment Research
Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.
Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?
05:49pm, Monday, 24'th Jan 2022 Zacks Investment Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have gained from rising admissions and higher revenues.
Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?
06:49pm, Friday, 21'st Jan 2022 Zacks Investment Research
Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More
05:51pm, Thursday, 20'th Jan 2022 Zacks Investment Research
Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
04:29pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
01:05pm, Wednesday, 19'th Jan 2022
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
bluebird bio down 4% after FDA extends review for gene therapies
02:09pm, Tuesday, 18'th Jan 2022 Seeking Alpha
Shares of bluebird bio (BLUE) are down 4% in morning trading as the FDA as extended the reviews for biologics license applications for its gene therapies betibeglogene autotemcel
FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies
09:24am, Tuesday, 18'th Jan 2022
The FDA has extended the review period for Bluebird bio Inc's (NASDAQ: BLUE) biologics licensing applications (BLA) for its lentiviral vector gene therapies. The agency has pushed the applications
Why Bluebird Bio Stock Is Sinking This Week
01:37pm, Friday, 14'th Jan 2022 The Motley Fool
The biotech's latest corporate update wasn't well received by investors this week.
Why Bluebird Bio Stock Is Sinking This Week
08:37am, Friday, 14'th Jan 2022
The biotech's latest corporate update wasn't well received by investors this week.
Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference
05:11pm, Tuesday, 11'th Jan 2022 Benzinga
Bluebird bio Inc (NASDAQ: BLUE ) Full story available on Benzinga.com
bluebird bio outlines 2022 milestones for gene therapies at J.P. Morgan conference
01:08pm, Tuesday, 11'th Jan 2022 Seeking Alpha
bluebird bio (BLUE) announces planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook
Where bluebird bio Stands With Analysts
04:02pm, Thursday, 06'th Jan 2022 Business Insider Markets
Within the last quarter, bluebird bio (NASDAQ: BLUE ) has observed the following analyst ratings:
